Anúncio
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Anúncio
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors
Próximos SlideShares
Subcutaneous Epstein-Barr Virus–Positive Diffuse Large B Cell Lymphoma Follow...Subcutaneous Epstein-Barr Virus–Positive Diffuse Large B Cell Lymphoma Follow...
Carregando em ... 3
1 de 6
Anúncio

Mais conteúdo relacionado

Apresentações para você(20)

Similar a Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors(20)

Anúncio

Mais de ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY(20)

Anúncio

Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors

  1. 229 OBJECTIVE: To analyze the sonographic features of different histopathological subtypes of borderline ovarian tumors (BOTs) confirmed by pathology, and to study the ultrasound performances of various types in borderline ovarian tumors. STUDY DESIGN: Retrospective analysis was performed on the pathological results and ultrasound projection findings of 129 patients diagnosed as BOTs by ultra- sound department of our hospital from January 2012 to November 2019. All patients were confirmed by surgical pathology and scanned consecutively by the investiga- tors using transabdominal or transvaginal ultrasound examination. RESULTS: Serous borderline tumors (SBOTs) were observed, and the prevalence rate (53%) was signifi- cantly higher than that of other subtypes, and the prob- ability of bilateral lesions was higher (40%). The sono- gram often showed ultrasound features of papillary neoplasm in the lesion and good internal echo (p<0.05). Mucinous borderline ovarian tumors (MBOTs) were mostly unilateral lesions (86%). The prevalence was second only to SBOTs. Histomorphological exam- inations were divided into gastrointestinal-type and endocervical-type. Among them, the gastrointestinal type of MBOTs were mostly unilateral, and their in- cidence was higher than that of endocervical-type of MBOTs. Compared with other pathological subtypes, the gastrointestinal type is more likely to show the sonographic characteristics of huge space occupying in the pelvic and abdominal cavity (mean diameter >10 cm), polycystic, multiple septums, and poor internal echo (p<0.05). The ultrasonographic features of the endocervical-type of MBOTs were simi­ lar to those of SBOTs. Compared with gastrointestinal type, the so- nographic images showed smaller lesion diameter, less septal or cyst, and more papillary excrescences in the tumor (p<0.05). The borderline clear cell tumor is the intermediate transition between the clear cell ade- nofibroma and the clear cell carcinoma. The clinical manifestations are diverse and lack specificity. The his­ tology of sonography was mainly solid, and the multi- ple microcapsules were honeycomb-like. It can also be shown as cystic. Among the 169 patients with BOTs, 20 cases of SBOTs, 17 cases of MBOTs, and 10 cases of other rare subtypes were complicated with other diseases or multiple subtypes. This study did not find sig­ nificant ultrasonic characteristics were used for dis- tinguish them from other subtypes. CONCLUSION: BOTs is a common disease in women during the reproductive period. It is characterized by the development of malignant tumors. Its clinical and patho- logical subtypes are complex and diverse. It leads many doctors to use the terms “large pelvic mass” and “solid ovarian mass” for diagnosis because of their lack of ex- perience and understanding. (Anal Quant Cytopathol Histpa­thol 2021;43:229–234) Keywords: adenocarcinoma, mucinous; adenocar- Analytical and Quantitative Cytopathology and Histopathology® 0884-6812/21/4304-0229/$18.00/0 © Science Printers and Publishers, Inc. Analytical and Quantitative Cytopathology and Histopathology® Ultrasound Findings of Different Subtypes of Ovarian Borderline Tumors Yuehang Liu, M.D., and Zongli Yang, M.D. From the Department of Abdomen Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, PR China. Yuehang Liu is Resident Physician. Zongli Yang is Professor. Address correspondence to:  Yang Zongli, M.D., Department of Abdomen Ultrasound, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Shinan District, Qingdao 266000, Shandong Province, PR China (qingyichaosheng@126.com). Financial Disclosure:  The authors have no connection to any companies or products mentioned in this article.
  2. cinoma, serous; borderline ovarian tumors; diag- nostic imaging; ovarian neoplasms; papillary neo- plasms; prognosis; transvaginal ultrasound, ultra- sonography. According to its biological characteristics, ovarian borderline tumors (BOTs) are defined as an ovari- an tumors between benign and malignant ovarian tumors, which has a potential risk of develop- ing into malignant tumors. Compared with the same stage of ovarian cancer, the clinical outcome is better due to proliferation (mild-moderate cell dysplasia) and no obvious stoma infiltration. Com- mon types of BOTs are serous borderline ovarian tumors (SBOTs) and mucinous borderline ovarian tumors (MBOTs). Rare types include seromucin­ ous, endometrioid, clear cell, and Brenner tumors. The MBOTs are divided into gastrointestinal-type and endocervical-type.1 Since the pathological clas- sification of BOTs is complex and the histobio- logical characteristics are diverse, it is difficult to accurately identify the different pathological types, and ultrasound combined with various valuable clinical indicators are used to improve the accu- rate diagnosis of ovarian tumors. We aimed to explore the advantages and disadvantages of pre­ operative diagnosis of BOTs. Materials and Methods Information This study was retrospective. From January 2012 to November 2019, the pathological data of 129 patients diagnosed with BOTs by the Ultrasound Department and confirmed by pathology were col- lected. Among them, 69 cases of serous border- line tumor were diagnosed, 46 cases of mucinous tumors, 8 cases of endometrial, 2 cases of clear cell, 2 cases of seromucinous, and 2 cases of Brenner tumor (Table I). The patients ranged in age from 17–80 years, with a median age of 45. All patients were surgically resected and specimens were ob- tained intraoperatively. Postoperative pathological diagnosis results were obtained. Instruments and Methods Transabdominal ultrasound 3.5–5 Hz and trans- vaginal ultrasound 5–10 Hz were performed on all patients. Data were analyzed using SPSS Ver- sion 20 statistical software (IBM Corp., Released 2011, IBM SPSS Statistics for Windows, Version 20.0, Armonk, New York, USA). The χ2 test was used to analyze the Kruskal-Wallis test of multiple independent samples, and p<0.05 was statistically significant. When the larger means of mass could not be fully explored, the combined examination methods of transabdominal and transvaginal were used to ensure that the visual field was comprehensive and sufficient. The sonographic features of differ- ent pathological types were retrospectively ana- lyzed. Combined with clinical and pathological findings, the number of masses, the extent of in- volvement (unilateral or bilateral, left or right), and the shape of the mass (internal echo, papil- lary and papillary morphology, septal and septal morphological features, multilocular or single locu- lar) were analyzed and discussed. Results Incidence and Sonographic Characteristics of Each Subtype in 129 BOTs Patients Incidence of Two Common BOTs Subtypes and Ultra- sound Findings. The prevalence of SBOTs (53%) was significantly higher than that of other sub- types, and the probability of bilateral lesions was higher (40%). The sonogram often showed the ultrasonic characteristics of papillary neoplasm with single atrium, little separation, good internal echo, large number of papillary neoplasms, and irregular shape in the lesion (p<0.05) (Table II).2 MBOTs were mostly unilateral lesions (86%), and the prevalence rate was second only to the results of SBOTs. Histopathological examination was di­ vided into gastrointestinal type and endocervical type, of which gastrointestinal type was mostly unilateral lesions, and the incidence rate was high­ er than that of endocervical type. Although the in- 230 Analytical and Quantitative Cytopathology and Histopathology® Liu and Yang Table I  Pathological Data of 129 Patients with Ovarian Borderline Tumors Pathological classification SBOTs MBOTs Seromucinous Clear cell Endometrioid Brenner Unilateral 41 40 1 2 7 2 Bilateral 28 6 1 0 1 0 Total 69 46 2 2 8 2
  3. cidence of endocervical type was less than that of gastrointestinal type, the bilateral incidence (45%) was significantly higher than that of gastrointesti­ nal type. The gastrointestinal MBOTs with unilat- eral and larger diameter (mean diameter >10 cm) may be characterized by occupying a large pel- vic space, multiple cysts and septations, smooth capsule, and few definite solid or papillary neo- plasms found in the lesions. Regarding the sono- gram feature with poor echo in the lesion (p<0.05),3 endocervical-type of MBOTs and SBOTs have sim- ilar ultrasonic manifestations. Compared with gas- trointestinal MBOTs, the sonogram of these two types of tumors shows smaller lesion diameter, less compartmentalized cystic cavity, and more papil- lary neoplasms in the tumor (Table III).1 Incidence of the Remaining Rare Subtypes and Ultra- sound Findings. There were fewer cases of rare types of BOTs in this study, although the inci- dence was not statistically significant: 2 seromu- cinous type, 8 endometrial type, and 2 Brenner tumors were all rare types, and no significant ul- trasound findings were identified to distinguish other subtypes. The borderline clear cell tumor has some characteristic ultrasound findings. Clear cell tumors are intermediate transitions between clear cell adenofibroma and clear cell carcinoma. The ages of the two patients with borderline clear cell tumors in this study were 55 and 69 years old, respectively. The clinical mani- festations were lack of specificity, often unilateral onset, may be accompanied by vaginal bleeding, abdominal distending local discomfort or pain, and so on. Acoustic histology showed a solid- dominated and multiple cystic cavity (Figure 1) with honeycomb-like structure and cystic.4 Concurrent BOTs with Other Diseases or Subtypes. There was 1 patient with bilateral SBOTs com­ plicated with left ovarian Brenner tumor, 1 patient with bilateral SBOTs complicated with right ovar- ian hyperdifferentiated serous adenocarcinoma, 1 patient with right SBOTs with pelvic giant het- erogeneous cystic mass (Figure 2), 2 patients with unilateral SBOTs with contralateral ovarian tera- toma, 6 patients with unilateral SBOTs complicat­ ed with serous cystadenoma, and 9 patients with Volume 43, Number 4/August 2021 231 Ultrasound Findings of Ovarian Borderline Tumors Table II  Sonographic Features of 129 Ovarian Borderline Tumors Ultrasound Feature findings SBOTs MBOTs Seromucinous Clear cell Endometrioid Brenner Location of lesion Left 18 13 1 1 1 2 Right 22 19 0 1 5 0 Bilateral 26 6 1 0 1 0 Pelvic/retroperitoneal 3 8 0 0 1 0 Maximum diameter, Approximate value 18 25 10 6 9 10   cm Unable to measure 1 5 0 0 0 0 Separation Multiple 13 37 2 2 4 2 Single 47 6 0 0 3 0 No/solid 9 3 0 0 1 0 Papillae Yes 61 12 2 0 3 1 No 8 34 0 2 5 1 Internal echo Good 59 5 0 1 0 1 Poor 10 41 2 1 8 1 Table III  Ultrasound Characteristics of Different Pathological Subtypes of Mucinous Borderline Ovarian Tumors Average Pathological diameter, classification Number Bilateral Unilateral cm Papillae Separation Gastrointestinal type 35 1 34 13 4 33 Endocervical 11 5 6 8 7 4
  4. unilateral SBOTs with low-grade invasive ovarian cancer. MBOTs Complicated with Other Diseases or Subtypes. We identified 1 patient with right MBOTs com­ plicated with left ovarian goiter, 1 patient with right MBOTs with a cancerous side with ovarian Brenner tumor, 2 patients with unilateral MOBTs complicated with ectopic endometrium, and 13 pa- tients with hyperdifferentiated mucinous adenocar- cinoma. Other Rare Subtypes. We identified 1 patient with right endometrial BOTs complicated with left ovarian serous cystadenoma, 2 patients with en- dometrial BOTs complicated with hyperdifferen­ tiated endometrial adenocarcinoma with secretion, 3 patients with endometrial BOTs complicated with tumor cystic wall ectopic cyst, 1 case of left sero­ mucinous BOTs with partial carcinogenesis, squa- mous metaplasia, and endometriosis, and 1 case of right clear cell BOTs complicated with highly differentiated clear cell carcinoma with left ovar- ian serous cystadenoma. Both ovarian Brenner tu- mors in this study were associated with other con- current subtypes (Table IV). Discussion Borderline ovarian tumors are one of the common diseases in women in reproductive stage. The World Health Organization included it in the clas- sification of ovarian tumor tissue in 1973. Because of the large number of BOT pathological subtypes, there is no typical symptom differentiation among the subtypes. BOTs have the histological charac- teristics of malignant tumors. The range of plasma CA125 and CA199 elevation in borderline tumor patients is large, not lending itself to becoming the diagnostic standard.5 In this study, 110 (86%) of 129 patients came to our department with a pelvic mass. It was found that the resolution of transabdominal ultrasound in the fine structures such as papillary neoplasm in the capsule was worse than that of transvagi- 232 Analytical and Quantitative Cytopathology and Histopathology® Liu and Yang Figure 1  The left borderline clear cell tumor of the ovary is complicated with intraepithelial canceration and microinfiltration. Ultrasound showed that the solid was mainly accompanied by a small cystic cavity. Figure 2  Serous borderline tumor of the ovary with intraepithelial canceration with ovarian torsion bleeding. Large pelvic mass was diagnosed by ultrasound.
  5. nal. However, the range of lesions was better than transvaginal ultrasound. The papillae in the ultra- sound images showed solid protuberances with a height ≥3 mm and a width ≤10 mm from the sac wall or from the compartment.6 Papillary neoplasm is the characteristic sonographic manifestation of borderline ovarian tumor, but some benign and malignant ovarian lesions can also show papillary structure, but BOTs are more irregular neoplasm.7 The crescent sign of the ovary is defined as the normal ovarian tissue near the tumor with or without follicles, located near the cystic wall, sur- rounded by the tumor, which is not separated from the ovarian envelope when properly pres- surized. Application to exclude invasive ovarian cancer8 when a healthy ovarian group is found near the tumor. The presence of multiple papillae and ovarian crescent sign is typical of SBOTs or endocervical-type.9 The honeycomb nodules are mainly solid multilocular nodules, cystic cavity number ≥10%, and the cystic area mostly origi- nates from the cystic wall. Honeycomb nodules are highly suggestive of gastrointestinal-type, and when a multilocular cyst ≥10 microcystic cavi- ties, possible gastrointestinal MBOTs should be considered (Figure 3).10 However, typical features are absent in a third of the cases, and these cases are usually misdiagnosed.11 This retrospective study compared the operation of patients post- pathological results, and preoperative ultrasound diagnosis found that most of the preoperative ultrasound diagnoses used terms such as “pelvic and abdominal giant mass,” “ovarian cystic solid mass,” and other morphological descriptions. Few senior experts can diagnose possible BOTs, due to lack of experience and inadequate understand- ing of the disease, as well as the fact that BOTs can include a variety of diseases and features and diagnostic significance of ultrasound findings are easily masked, coupled with some metastatic ovar- ian tumors, such as gastric ring cell carcinoma complicated by Krukenberg tumor, or metastatic ovarian space occupying from appendiceal ade- nocarcinoma, all of which increased the diagnostic difficulties of ultrasound doctors. On the other hand, many studies have attempt- ed to use systematic assessment methods to estab- lish a standardized scoring model to evaluate the classification of ovarian masses, simple criteria and logistic regression models such as IOTA (Interna- tional Association for Ovarian Tumor Analysis), classified from tumor morphological sonographic manifestations.12 The risk of malignancy index (RMI) classifies by the condition of the capsule, the size of the capsule, the age of the patient (divided by 50 years of age), and ascites to predict malig- Volume 43, Number 4/August 2021 233 Ultrasound Findings of Ovarian Borderline Tumors Table IV Significant Differences in Sonographic Characteristics of Different Pathological Types Sonographic features of Internal 6 subtypes Papillae Separation echo χ2 46.427 51.430 72.375 p Value <0.05* <0.05* <0.05* *p<0.05, the sonographic characteristics of different pathological types were statistically significant. Figure 3  (Left) Typical sonogram of a serous borderline tumor. (Right) Typical sonogram of a mucinous borderline tumor.
  6. nant risk for ovarian masses.13 These methods which distinguish between benign and malignant ovarian tumors have high accuracy, but the diag- nostic rate in BOTs is generally low. With the popularity of 3D technology in recent years, some scholars have tried to use new technology to find the difference from the previous 2D diagnosis. Unfortunately, there is no definite evidence that 3D ultrasound is superior to the traditional 2D examination in diagnostic BOTs.14 The sonographic characteristics of borderline ovarian tumors with different pathological sub- types were compared in this retrospective ana­ lysis. The number of samples of individual rare types still needs to be improved in subsequent studies. Although ultrasound is still very limited in the accurate diagnosis of various subtypes of BOTs, ultrasound, as a noninvasive method, has unparalleled advantages in the changes of tissue morphology, involvement range, fine structure, post-operative, and recurrence of the mass. As technology advances and our understanding of the disease deepens, ultrasound will be more useful for preoperative evaluation and surgical procedures in BOTs patients, providing great clinical value. References   1.  Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A: Gynecologic Cancer InterGroup (GCIG) consen- sus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014;24(9 Suppl 3):S5-8  2. Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 2013;24(Suppl 10): 16-21   3.  Brown J, Frumovitz M: Mucinous tumors of the ovary: Cur- rent thoughts on diagnosis and management. Curr Oncol Rep 2014;16(6):389  4. Zhao C, Wu LS, Barner R: Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: Clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2011;2:94-106   5.  Solmaz Hasdemir P, Guvena T: Borderline ovarian tumors: A contemporary review of clinicopathological characteris- tics, diagnostic methods and therapeutic options. J BUON 2016;21(4):780-786  6. Grigore M: HDlive imaging of a serous borderline ovarian tumor. Ultrasound Obstet Gynecol 2013 May;41(5):598-599  7. Timor-Tritsch IE, Foley CE, Brandon C, Yoon E, Ciaffarra- no J, Monteagudo A, Mittal K, Boyd L: New sonographic marker of borderline ovarian tumor: Microcystic pattern of papillae and solid components. Ultrasound Obstet Gynecol 2019;54(3):395-402  8. Moro F, Baima Poma C, Zannoni GF, Vidal Urbinati A, Pasciuto T, Ludovisi M, Moruzzi MC, Carinelli S, Franchi D, Scambia G, Testa AC: Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non- invasive malignant serous ovarian tumors. Ultrasound Ob- stet Gynecol 2017;50(6):788-799  9. Yazbek J, Raju KS, Ben-Nagi J, Holland T, Hillaby K, Jur­ kovic D: Accuracy of ultrasound subjective ‘pattern rec- ognition’ for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 2007;29(5):489-495 10. Moro F, Zannoni GF, Arciuolo D, Pasciuto T, Amoroso S, Mascilini F, Mainenti S, Scambia G, Testa AC: Imaging in gynecological disease (11): Clinical and ultrasound features of mucinous ovarian tumors. Ultrasound Obstet Gynecol 2017;50(2):261-270 11. Fruscella E, Testa AC, Ferrandina G, De Smet F, Van Holsbeke C, Scambia G, Zannoni GF, Ludovisi M, Achten R, Amant F, Vergote I, Timmerman D: Ultrasound features of different histopathological subtypes of borderline ovar- ian tumors. Ultrasound Obstet Gynecol 2005;26(6):644-650 12.  Shimada K, Matsumoto K, Mimura T, Ishikawa T, Munechika J, Ohgiya Y, Kushima M, Hirose Y, Asami Y, Iitsuka C, Miyamoto S, Onuki M, Tsunoda H, Matsuoka R, Ichizuka K, Sekizawa A: Ultrasound-based logistic regression model LR2 versus magnetic resonance imaging for discriminating between benign and malignant adnexal masses: A prospec- tive study. Int J Clin Oncol 2018;23(3):514-521 13.  Zhang S, Yu S, Hou W, Li X, Ning C, Wu Y, Zhang F, Jiao YF, Lee LTO, Sun L: Diagnostic extended usefulness of RMI: Comparison of four risk of malignancy index in pre- operative differentiation of borderline ovarian tumors and benign ovarian tumors. J Ovarian Res 2019;12(1):87 15. Alcázar JL, Jurado M: Three-dimensional ultrasound for assessing women with gynecological cancer: A systematic review. Gynecol Oncol 2011;120(3):340-346 234 Analytical and Quantitative Cytopathology and Histopathology® Liu and Yang
Anúncio